Scarica l'app Stockscreener
86.94
0.92%
0.775
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$86.17
Aprire:
$85.65
Volume 24 ore:
262.69K
Relative Volume:
0.15
Capitalizzazione di mercato:
$16.98B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
19.77
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+1.16%
1M Prestazione:
+0.50%
6M Prestazione:
+53.10%
1 anno Prestazione:
+33.23%
Intervallo 1D:
$85.55
$87.19
Intervallo di 1 settimana:
$84.38
$92.86
Portata 52W:
$53.56
$92.86
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
86.93 | 16.83B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.11 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.01 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.00 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
847.23 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.59 | 35.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte's Quarterly Earnings Preview: What You Need To Know - Barchart.com
Real time alert setup for Incyte Corporation performance2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Is Incyte Corporation (ICY) stock undervalued by metricsWeekly Trend Summary & Safe Capital Investment Plans - newser.com
Is Incyte Corporation (ICY) stock dividend growth reliable2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
What’s next for Incyte Corporation stock priceMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com
Is Incyte Corporation (ICY) stock among top earnings plays2025 Volume Leaders & Real-Time Volume Surge Alerts - nchmf.gov.vn
Will Incyte Corporation (ICY) stock enhance shareholder valueEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - newser.com
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice - sharewise.com
Multi asset correlation models including Incyte Corporation2025 Price Targets & Precise Trade Entry Recommendations - newser.com
Incyte to Report Third Quarter 2025 Financial Results on October 28 - MyChesCo
Lobbying Update: $80,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Incyte (INCY) Reports Encouraging Clinical Trial Data at ESMO Co - GuruFocus
Incyte at ESMO Congress 2025: Strategic Focus on Tumor Programs - Investing.com
Incyte’s cancer drug candidates show promising results in trials - Investing.com
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - The AI Journal
What technical charts say about Incyte Corporation stockLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn
Is Incyte Corporation stock a defensive play in 20252025 Big Picture & Reliable Entry Point Trade Alerts - nchmf.gov.vn
Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled! - TipRanks
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyWeekly Trend Summary & Real-Time Volume Trigger Notifications - nchmf.gov.vn
How Incyte Corporation stock performs in rising dollar environmentMarket Performance Summary & Proven Capital Preservation Tips - newser.com
Does Incyte Corporation show high probability of reboundMarket Activity Summary & Safe Entry Point Alerts - newser.com
InvestingPro’s Fair Value model captures 63% gain in Incyte shares By Investing.com - Investing.com
Will Incyte Corporation (ICY) stock see insider accumulationMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - newser.com
How Incyte Corporation stock responds to policy changesTrade Volume Report & Consistent Return Strategy Ideas - newser.com
Incyte (INCY) Stock Is Up, What You Need To Know - Barchart.com
Incyte Corporation stock hits 52-week high at 88.78 USD - Investing.com
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Can Incyte Corporation rally from current levels2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com
Sjogren's Syndrome Market Insights Highlight Expanding - openPR.com
Incyte Canada Announces Health Canada approval of Opzelura® (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11 - Yahoo
Using Python tools to backtest Incyte Corporation strategiesMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 - The Globe and Mail
Incyte stock price target raised to $76 from $68 at UBS on valuation By Investing.com - Investing.com South Africa
Incyte stock price target raised to $76 from $68 at UBS on valuation - Investing.com India
How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook - Yahoo Finance
Incyte Corp. stock rises Monday, still underperforms market - MarketWatch
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - BioSpace
Incyte jumps amid takeover speculation - MSN
How Incyte Corporation stock compares to market leadersWeekly Trade Report & Weekly Hot Stock Watchlists - newser.com
Incyte (INCY) Announces Promising Study Results for Cancer Treat - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock - MarketBeat
RBC Capital Remains a Hold on Incyte (INCY) - The Globe and Mail
What 14 Analyst Ratings Have To Say About Incyte - Benzinga
Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus
Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat
Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Oct 15 '25 |
Sale |
85.13 |
277 |
23,581 |
26,569 |
2.03%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):